Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...

Centre abdicates its constitutional obligation, criticises patients and experts on SMA issue: Our Bureau, New Delhi Friday, January 24, 2025, 18:15 Hrs [IST] Patients and public h ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

A registry for rare disease patients in the state will become a reality this year, State Health Minister Veena George said on ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Kochi: The central govt has informed the Kerala high court that there are more than 3,000 registered Group III rare diseases patients across 12 centre.

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New ...

The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...